1h Free Analyst Time
The inhaled nitric oxide market is poised to grow by $353.77 mn during 2022-2026, accelerating at a CAGR of 8.6% during the forecast period. The report on the inhaled nitric oxide market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the use of inhaled nitric oxide in cardiac surgeries, favorable government initiatives, and a rise in research and development activities.
The inhaled nitric oxide market analysis includes the application segment and geographic landscape.
The inhaled nitric oxide market is segmented as below:
By Application
- Neonatal respiratory treatment
- Chronic obstructive pulmonary disease (COPD)
- Acute respiratory distress syndrome (ARDS)
- Others
By Geographical Landscape
- North America
- APAC
- Europe
- South America
- Middle East and Africa
This study identifies the rise in the number of patients with COPD as one of the prime reasons driving the inhaled nitric oxide market growth during the next few years. Also, an increase in the prevalence of diseases in newborns and FDA encouragement for clinical inhaled nitric oxide will lead to sizable demand in the market.
The report on inhaled nitric oxide market covers the following areas:
- Inhaled nitric oxide market sizing
- Inhaled nitric oxide market forecast
- Inhaled nitric oxide market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading inhaled nitric oxide market vendors that include Bellerophon Therapeutics Inc., Berkeley Life and L2G North America Inc., Beyond Air Inc., Cigna Corp., Circassia Group PLC, Geno Pharmaceuticals Pvt. Ltd., Getinge AB, Halma Plc, HumanN, Inspiration Healthcare Group Plc, L Air Liquide SA, Linde Plc, Mallinckrodt Plc, Merck KGaA, Moda Health Plan Inc., Nu Med Plus Inc., Uniscience Group, and VERO Biotech. Also, the inhaled nitric oxide market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Application
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global inhaled nitric oxide market: Bellerophon Therapeutics Inc., Berkeley Life and L2G North America Inc., Beyond Air Inc., Cigna Corp., Circassia Group PLC, Geno Pharmaceuticals Pvt. Ltd., Getinge AB, Halma Plc, HumanN, Inspiration Healthcare Group Plc, L Air Liquide SA, Linde Plc, Mallinckrodt Plc, Merck KGaA, Moda Health Plan Inc., Nu Med Plus Inc., Uniscience Group, and VERO Biotech.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is the rise in the number of patients with copd.`
According to the report, one of the major drivers for this market is the use of inhaled nitric oxide in cardiac surgeries.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bellerophon Therapeutics Inc.
- Berkeley Life and L2G North America Inc.
- Beyond Air Inc.
- Cigna Corp.
- Circassia Group PLC
- Geno Pharmaceuticals Pvt. Ltd.
- Getinge AB
- Halma Plc
- HumanN
- Inspiration Healthcare Group Plc
- L Air Liquide SA
- Linde Plc
- Mallinckrodt Plc
- Merck KGaA
- Moda Health Plan Inc.
- Nu Med Plus Inc.
- Uniscience Group
- VERO Biotech
